Quick Comparison: Which Receptors Does Each Compound Target?

The most important takeaway is that the phrase dual-receptor agonist does not describe one universal mechanism. Tirzepatide combines GLP-1 with GIP signaling, while Survodutide and Mazdutide combine GLP-1 with glucagon signaling. Retatrutide includes all three receptor systems.

Understanding the Three Metabolic Signaling Pathways

To understand the differences among these compounds, it helps to separate the three receptor pathways involved.

GLP-1 Receptor Signaling

GLP-1 stands for glucagon-like peptide-1. GLP-1 receptors participate in nutrient-responsive communication involving the digestive system, pancreas, brain and other tissues. Research commonly examines glucose-dependent insulin signaling, glucagon regulation, gastrointestinal signaling, satiety-related signaling and broader metabolic coordination.

All four compounds in this comparison include GLP-1 receptor activity. That shared feature places them within the broader field of incretin and metabolic-signaling research, but it does not make their full pharmacological profiles identical.

GIP Receptor Signaling

GIP stands for glucose-dependent insulinotropic polypeptide. It is another nutrient-responsive signaling molecule. Researchers study GIP receptor activity in relation to glucose-dependent insulin signaling, nutrient handling, adipose-tissue biology and communication between metabolic pathways.

Tirzepatide and Retatrutide include GIP receptor agonism. Survodutide and Mazdutide do not use GIP receptor activation as part of their defining dual-receptor profiles.

Glucagon Receptor Signaling

The glucagon receptor is central to research involving hepatic glucose production, stored-energy mobilization, lipid metabolism, substrate use and energy expenditure. Glucagon receptor activity therefore introduces a different experimental question from GIP receptor activity.

Survodutide, Mazdutide and Retatrutide include glucagon receptor agonism. Tirzepatide does not.

What Is Tirzepatide?

Tirzepatide is a dual agonist of the GIP and GLP-1 receptors. Its research profile is built around two incretin-related signaling pathways rather than the GLP-1/glucagon pairing used by Survodutide and Mazdutide.

Published research has examined Tirzepatide in metabolic and glucose-regulation models, including randomized clinical studies. For a focused explanation of the compound and its two receptor targets, read the Mile High Peptides Tirzepatide research guide.

Why Tirzepatide Is a Useful Comparison Point

Tirzepatide provides a clear example of dual-receptor signaling that does not involve the glucagon receptor. Comparing it with Survodutide and Mazdutide helps researchers distinguish between two different dual-agonist strategies:

• GIP plus GLP-1 receptor activity
• Glucagon plus GLP-1 receptor activity

This distinction matters because GIP and glucagon participate in different biological signaling networks.

What Is Survodutide?

Survodutide, also known by the development designation BI 456906, is a dual glucagon and GLP-1 receptor agonist. Researchers study it to examine how GLP-1-related nutrient signaling interacts with glucagon-related hepatic and energy-regulation pathways.

Its glucagon receptor activity separates it from Tirzepatide, even though both compounds are described as dual agonists. Survodutide has also been investigated in research involving obesity and metabolic dysfunction-associated steatohepatitis, with conclusions limited to the populations and study designs examined.

Read the complete Survodutide (BI 456906) research guide for a closer look at its terminology and receptor pathways.

What Is Mazdutide?

Mazdutide is also known as IBI362 and LY3305677. Like Survodutide, it is classified as a dual glucagon and GLP-1 receptor agonist. Its research profile therefore includes the same two broad receptor categories, but Mazdutide and Survodutide are separate molecules with distinct structures, receptor-activity profiles, development histories and bodies of evidence.

It would be inaccurate to treat them as equivalent or assume that results observed with one compound predict results with the other. Even compounds aimed at the same receptor pair may differ in relative receptor activity, exposure, study population, trial design and measured outcomes.

For its alternate names and a more detailed pathway explanation, visit the Mazdutide (IBI362) research guide.

What Is Retatrutide?

Retatrutide, also identified in scientific literature as LY3437943, is a triple agonist involving GIP, GLP-1 and glucagon receptors. Its defining research feature is the inclusion of all three pathways represented across the other compounds in this comparison.

This does not mean Retatrutide is simply Tirzepatide with glucagon added, nor does it establish that three receptor targets are automatically better than two. The compound has its own molecular design and receptor-activity balance, and it must be evaluated through its own evidence.

A published phase 2 trial described Retatrutide as an agonist of the GIP, GLP-1 and glucagon receptors. Researchers are also directly studying Retatrutide and Tirzepatide in a registered comparative trial, reinforcing why these compounds should be compared through controlled evidence rather than assumptions.

Read the Retatrutide (GLP-R3) research guide for a focused overview.

Dual- vs. Triple-Receptor Agonists: What Is the Research Difference?

A receptor agonist activates a receptor and initiates biological signaling. A dual agonist is designed to activate two receptor types, while a triple agonist is designed to activate three.

The number of receptors is only the beginning of the comparison. Researchers must also consider:

• Receptor combination: Which two or three receptors are involved?
• Relative activity: How strongly does the compound activate each receptor?
• Molecular structure: How is the compound designed, and how does that affect its behavior?
• Experimental model: Was the evidence produced in vitro, in animals or in a defined clinical population?
• Study duration: Were researchers observing short-term signaling or longer-term outcomes?
• Endpoints: Did the study measure glucose-related markers, body composition, liver markers, energy expenditure, adverse events or something else?
• Evidence maturity: How much replicated and independently evaluated evidence exists?

For these reasons, “dual versus triple” is not enough to determine how two compounds compare. The specific receptor combination and the evidence for the individual molecule are more informative than receptor count alone.

Why Survodutide and Mazdutide Are Not the Same

Survodutide and Mazdutide are the easiest pair to confuse because both activate GLP-1 and glucagon receptors. However, sharing receptor targets does not make two research compounds identical.

A useful analogy is that two keys may open the same two doors while interacting with each lock differently. In receptor research, molecular structure and relative activity can influence the strength, timing and balance of the signals being studied.

Researchers should therefore review compound-specific publications rather than combining the evidence under one broad “GLP-1/glucagon agonist” label.

Can Results From These Compounds Be Compared Directly?

Cross-trial comparisons require caution. Separate studies may enroll different populations, use different durations, examine different endpoints and apply different analytical methods. A larger numerical change reported in one study does not establish superiority over a compound evaluated in another study.

A true comparative conclusion is strongest when compounds are examined head-to-head within the same randomized protocol. Until comparable evidence is available, the scientifically responsible approach is to describe what each study found without presenting separate trials as though they were one experiment.

How These Compounds Fit Into Metabolic Research

Together, these four compounds illustrate the movement from single-pathway research toward integrated metabolic signaling models:

1. GLP-1 provides a shared foundation. All four compounds include GLP-1 receptor activity.
2. Tirzepatide adds GIP. It provides a model for combined incretin-receptor signaling.
3. Survodutide and Mazdutide add glucagon instead. They allow investigation of GLP-1 signaling alongside hepatic and energy-regulation pathways associated with the glucagon receptor.
4. Retatrutide includes GIP and glucagon. It brings three distinct receptor pathways into a single compound-specific research model.

Researchers can explore additional compounds and product formats through the Mile High Peptides Metabolic & Body Composition research category or visit the Peptide Research Education Hub for more pathway-focused guides.

Frequently Asked Questions

What is the primary difference between Tirzepatide and Retatrutide?

Tirzepatide activates GIP and GLP-1 receptors. Retatrutide activates GIP, GLP-1 and glucagon receptors. Retatrutide therefore includes one additional receptor pathway, but the compounds also have different molecular designs and must be evaluated individually.

What is the difference between Tirzepatide and Survodutide?

Both include GLP-1 receptor activity, but their second receptor differs. Tirzepatide activates the GIP receptor, while Survodutide activates the glucagon receptor.

What is the difference between Tirzepatide and Mazdutide?

Tirzepatide is a dual GIP/GLP-1 receptor agonist. Mazdutide is a dual glucagon/GLP-1 receptor agonist. Their shared GLP-1 activity does not make their overall signaling profiles equivalent.

Are Survodutide and Mazdutide the same compound?

No. Both target GLP-1 and glucagon receptors, but they are distinct molecules with different research identifiers, structures, development programs and compound-specific evidence.

Which compound targets the most receptors?

Retatrutide targets three receptors: GIP, GLP-1 and glucagon. The other compounds in this comparison target two receptors. Receptor count by itself does not establish comparative effectiveness, safety or research suitability.

Does “triple agonist” mean better than “dual agonist”?

No. It only describes the number of receptor types included in the compound’s activity profile. Scientific comparisons require compound-specific and, ideally, head-to-head evidence.

Can findings from one of these compounds be applied to another?

Not automatically. Researchers must consider the molecule, receptor balance, experimental model, population, study design and endpoints before interpreting or comparing findings.

Where can I learn more about each compound?

Use the individual Mile High Peptides guides for Tirzepatide, Survodutide, Mazdutide and Retatrutide.

Key Takeaway

Tirzepatide, Survodutide, Mazdutide and Retatrutide are connected by their relevance to multi-receptor metabolic research, but their receptor combinations distinguish them:

• Tirzepatide: GIP + GLP-1
• Survodutide: glucagon + GLP-1
• Mazdutide: glucagon + GLP-1
• Retatrutide: GIP + GLP-1 + glucagon

The strongest comparison does not ask which receptor count sounds most advanced. It asks which signaling pathways are involved, how the individual compound engages them and what the compound-specific evidence actually supports.

Scientific References

1. Tirzepatide as a dual GIP and GLP-1 receptor agonist: randomized phase 3 research
2. Survodutide as a glucagon and GLP-1 receptor dual agonist: randomized phase 2 research
3. Mazdutide as a glucagon and GLP-1 receptor dual agonist: randomized phase 2 research
4. Retatrutide as a GIP, GLP-1 and glucagon receptor agonist: randomized phase 2 research
5. Registered Retatrutide versus Tirzepatide comparative study